1 / 5

FDA’s Third Annual MDUFMA Stakeholder Meeting November 17, 2005

FDA’s Third Annual MDUFMA Stakeholder Meeting November 17, 2005. “The User Fee Structure” Mark Leahey, Executive Director Medical Device Manufacturers Association (MDMA). User Fees before MDUFSA. Volatile and unpredictable for the industry Fees increased between 55-60% in just two years

gwidon
Télécharger la présentation

FDA’s Third Annual MDUFMA Stakeholder Meeting November 17, 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA’s Third Annual MDUFMA Stakeholder Meeting November 17, 2005 “The User Fee Structure” Mark Leahey, Executive Director Medical Device Manufacturers Association (MDMA)

  2. User Fees before MDUFSA • Volatile and unpredictable for the industry • Fees increased between 55-60% in just two years • PMA fee from $154,000 (FY03) to $239,237 (FY05) • 510(k) fee from $2,187 (FY03) to $3,502 (FY05) • Allowed FDA to collect more $ per submission if they saw a decline in fee generating submissions • Increases were unsustainable for 99% of the industry • Fee generating submissions dropped significantly after the user fee was created

  3. User Fees after MDUFSA • Fees are much more predictable for the industry • Fees increases capped at 8.5% annually (MDMA recommended inflation) • Eliminated the workload and compensating adjustments (MDMA recommendation from 2002 & previous two stakeholder meetings) • Provided greater fee relief for companies under $100million in annual revenues (MDMA recommendation from 2002)

  4. User Fees -What’s Ahead • Evaluate the value of user fees • Fees must be reasonable & rational • Look at fees and performance together • Need to ensure that fees do not increase at unsustainable rates • Understanding that fees are meant to be additive to appropriations and not a substitute • Determine FDA’s actual resource needs related to the premarket review program

  5. User Fees -What’s Ahead • Looking forward to working with the FDA, the Hill and other stakeholders to ensure that patients have timely access to safe and effective medical technologies and that smaller companies continue to have the ability to innovate

More Related